-
Adagene Inc NASDAQ:ADAG Adagene Inc. is a platform-driven, clinical-stage biopharmaceutical company committed to transforming the discovery and development of novel antibody-based cancer immunotherapies. Adagene combines computational biology and artificial intelligence to design novel antibodies that address unmet patient needs. Its proprietary pipeline is comprised of novel immunotherapy programs. Adagene has forged strategic collaborations with reputable global partners that leverage its technology in multiple approaches at the vanguard of science.
Location: 4f, Building C14, No. 218,, Xinghu Street, Suzhou Industrial Park, Jiangsu, 215123, China (Mainland) | Website: www.adagene.com | Industry: Pharmaceutical Preparation Manufacturing | Sector: Manufacturing
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
44.65M
Cash
95.67M
Avg Qtr Burn
-7.10M
Short % of Float
0.13%
Insider Ownership
10.66%
Institutional Own.
25.35%
Qtr Updated
06/30/24
Drug Pipeline
Powered by
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
ADG126 (CTLA4) + Pembrolizumab Details Cancer, Solid tumor/s, Colorectal cancer | Phase 1/2 Data readout | |
ADG116 (CTLA4) Details Solid tumor/s, Cancer | Phase 1/2 Update | |
ADG106 (CD137) Details Solid tumor/s, Cancer, Non-small cell lung carcinoma, Breast cancer, ER+/HER2- breast cancer | Failed Discontinued |